Emerg Infect Dis. 2018 Mar;24(3):534-540. doi: 10.3201/eid2403.171633.
Interferon-γ release assays (IGRAs) are the preferred diagnostic test for tuberculosis (TB) infection in at-risk populations in developed countries. However, IGRAs have high false-negative rates in patients with TB disease. Population-based studies assessing the factors associated with negative IGRA results in TB patients have not been performed. Using statewide TB surveillance data of culture-confirmed TB patients in Texas, USA, during 2013-2015, we describe the patient characteristics and treatment outcomes associated with false-negative IGRA results. Among 2,854 TB patients, 1,527 (53.5%) had an IGRA result; 97.4% (1,487/1,527) of those had a positive (87.7%) or negative (12.3%) result. Older age, HIV co-infection, non-Hispanic white race/ethnicity, and being tested with T-SPOT.TB were associated with negative IGRA results. TB patients with negative IGRA results had a higher mortality, potentially due to delayed treatment. Healthcare providers should consider these risk factors when making decisions for patients with suspected TB and negative IGRA results and potentially provide treatment.
干扰素-γ 释放试验(IGRAs)是发达国家高危人群中用于诊断结核分枝杆菌(TB)感染的首选检测方法。然而,IGRAs 在患有结核病的患者中存在高假阴性率。尚未进行基于人群的研究来评估与 TB 患者 IGRA 阴性结果相关的因素。本研究使用美国德克萨斯州 2013-2015 年期间经培养确诊的 TB 患者的全州性 TB 监测数据,描述了与 IGRA 阴性结果相关的患者特征和治疗结局。在 2854 例 TB 患者中,有 1527 例(53.5%)进行了 IGRA 检测;其中 1487 例(97.4%)的检测结果为阳性(87.7%)或阴性(12.3%)。年龄较大、HIV 合并感染、非西班牙裔白人种族/民族以及使用 T-SPOT.TB 检测与 IGRA 阴性结果相关。IGRA 阴性结果的 TB 患者死亡率更高,可能是由于治疗延迟所致。医疗保健提供者在为疑似结核病且 IGRA 阴性结果的患者做出决策时,应考虑这些风险因素,并可能需要提供治疗。